Global Glioblastoma Multiforme Treatment Market Overview

The Global Glioblastoma Multiforme Treatment Market size is estimated to reach $3.24 Billion by 2026, growing at a CAGR of 8.1% over the forecast period of 2021-2026.

Glioblastoma is a tumor that can develop in the brain or spinal cord and is very aggressive. Glioblastoma arises from astrocytes, which are cells that support nerve cells. Glioblastoma may strike anyone at any age, although it frequently strikes older people. It can make headaches, nausea, vomiting, and seizures worse.

Surgery is the mainstay of Glioblastoma Multiforme treatment, followed by radiation and chemotherapy. The main goal of surgery is to remove as much of the tumour as possible without harming the normal brain tissue required for optimal neurological function.

Glioblastoma Multiforme tumors, on the other hand, are surrounded by a zone of moving, infiltrating tumor cells that infiltrate neighboring tissues, making complete removal difficult.

Impact of COVID-19 on glioblastoma multiforme Treatment Market

The Covid 19 outbreak has wreaked havoc on the worldwide healthcare system. Our organization has demonstrated the difficulties we experienced in treating patients with the hazardous Glioblastoma multiforme cancer. The increased risk of Covid 19 infection in cancer patients could lead to devastating complications and a poor outcome.

The non-standard strategy of keeping patients on tab temozolamide only after surgery or on a hypofractionated radiotherapy course resulted in symptomatic relief in patients under 70 years of age, with only 2% of patients over 70 years of age showing the progression of disease on check MRI scans. In covid-19 crises, this method can be explored; however, it is not conventional.

Key Takeaways from Global Glioblastoma Multiforme Treatment Market Report:

• Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units), and Value ($M) data given at country level – for treatment, drug class, end-use, and by different industry verticals.
• Understand the different market dynamics – key driving factors, challenges, and hidden opportunities.
• Get in-depth insights on your competitor’s performance – market shares, strategies, financial benchmarking, product benchmarking, SWOT, and more.
• Analyze the sales and distribution channels across key geographies to improve top-line revenues.
• Understand the industry supply chain with a deep dive on the value augmentation at each step to optimize value and bring efficiencies in your processes.
• Get a quick outlook on the market entropy – M&As, deals, partnerships, product launches of all key players for the past 4 years.
• Evaluate the supply-demand gaps, import-export statistics, and regulatory landscape for more than the top 20 countries globally for the market.

Market Dynamics

Driver: 

Increasing prevalence of Malignant Glioma drives the market demand

Glioblastoma Multiforme is the most common primary brain tumor in adults. It is a malignant astrocytoma. According to the American Society of Oncology, the number of new cases of high-grade gliomas increased by roughly 17000 in 2019.

Challenge:

Lack of effective therapies for glioblastoma multiforme is set to limit the market growth.

Major clinical trials for treating glioblastoma multiforme using small molecules have failed in recent years because the drugs did not reach therapeutic concentrations in the brain. Thus, understanding BBB function and physiology is critical for developing effective small molecule therapeutic options and avoiding costly clinical trials that fail.

In addition, the paucity of effective glioblastoma multiforme therapy options highlights the unmet need for effective target inhibition and medication delivery techniques.

By treatment, the market for Targeted Therapy is estimated to grow at the highest CAGR during the forecast period.

Based on Product, Global Glioblastoma Multiforme Treatment Market is segmented into Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field Therapy, and Immunotherapy. Radiation therapy dominated the market in 2020 owing to its rate. Radiation therapy can be used as a stand-alone treatment or with chemotherapy and surgery.

In the event of a brain tumor recurrence, it is also beneficial and highly recommended. When temozolomide is used with radiotherapy, the tumour becomes more susceptible to radiation. Therefore, this combination of treatments is more successful than radiotherapy alone. However, Targeted therapy is the fastest-growing, with a CAGR of 9.6% over 2021-2026.

The rising usage of targeted treatment to address GBM is likely to drive segment growth during the projected period. In addition, increased research initiatives to discover innovative targeted therapies for the condition are also expected to drive category growth.

By Drug Class, the market for Bevacizumab is estimated to grow at the highest CAGR during the forecast period.

By Applications, Others dominated the market in 2020. The other drugs segment includes everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA). Corticosteroids are commonly used to relieve symptomatic effects from peritumoral vasogenic edema. Because of its lack of mineralocorticoid action, dexamethasone is widely administered.

Furthermore, corticosteroids may have immunosuppressive effects, emphasizing the importance of focusing on the immune response for targeted therapy. However, Bevacizumab is the fastest growing, with a CAGR of 9.2% over 2021-2026. This is owing to approval of treatment and newly diagnosed Glioblastoma Multiforme.

Geographical Overview

The Asia Pacific to account for the largest market share during the forecast period

North America dominated the Global Glioblastoma Multiforme Treatment Market with a share of 37.9% in 2020. Government support for the healthcare sector’s development, a high level of awareness about rare illnesses, easy access to high-quality medical facilities, and attractive reimbursement policies are essential drivers driving the regional market growth.

However, Asia Pacific is set to be the fastest-growing over 2021-2026. This is due to the entrance of generics such as temozolomide in the Market, improving economics in Asia Pacific developing countries, and growing investments in the healthcare sector.

Key Market Players

Key Players in Global Glioblastoma Multiforme Treatment Market consist of Merck & Co., Inc.; Amgen, Inc.; F. Hoffmann-La Roche Ltd.; Pfizer Inc.; Amgen, Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Arbor Pharmaceuticals, LLC; Amneal Pharmaceuticals; Karyopharm Therapeutics, Inc.; among others.

Developments

In June 2019, Pfizer’s Zirabev, a biosimilar of Avastin, was authorized by the US Food and Drug Administration to treat recurrent glioblastoma, non-small cell lung cancer, and colorectal cancer, among other indications. The firm released its product in the United States in January 2020.

Report Coverage and Scope

The report “Global Glioblastoma Multiforme Treatment Market”, by Research Informatic covers an in-depth detailed analysis for the following segment, which are covered under the scope.

By Treatment

• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Tumor Treating Field Therapy
• Immunotherapy

By Drug Class

• Temozolomide
• Bevacizumab
• Lomustine
• Carmustine Wafers

By End-Use

• Hospitals
• Clinics
• Ambulatory Surgical Centers

Global Glioblastoma Multiforme Treatment Market Growth, Trend and Forecast 2021-2028

Chapter 1 Glioblastoma Multiforme Treatment Market Overview
1.1 Product Overview and Scope of Glioblastoma Multiforme Treatment
1.2 Glioblastoma Multiforme Treatment Market Segmentation by Type
1.2.1 Global Production Market Share of Glioblastoma Multiforme Treatment by Type in 2020
1.2.1 Type 1
1.2.2 Type 2
1.2.3 Type 3
1.3 Glioblastoma Multiforme Treatment Market Segmentation by Application
1.3.1 Glioblastoma Multiforme Treatment Consumption Market Share by Application in 2020
1.3.2 Application 1
1.3.3 Application 2
1.3.4 Application 3
1.4 Glioblastoma Multiforme Treatment Market Segmentation by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India
1.5 Global Market Size (Value) of Glioblastoma Multiforme Treatment (2014-2028)

Chapter 2 Global Economic Impact on Glioblastoma Multiforme Treatment Industry
2.1 Global Macroeconomic Environment Analysis
2.1.1 Global Macroeconomic Analysis
2.1.2 Global Macroeconomic Environment Development Trend
2.2 Global Macroeconomic Environment Analysis by Regions

Chapter 3 Global Glioblastoma Multiforme Treatment Market Competition by Manufacturers
3.1 Global Glioblastoma Multiforme Treatment Production and Share by Manufacturers (2020 and 2020)
3.2 Global Glioblastoma Multiforme Treatment Revenue and Share by Manufacturers (2020 and 2020)
3.3 Global Glioblastoma Multiforme Treatment Average Price by Manufacturers (2020 and 2020)
3.4 Manufacturers Glioblastoma Multiforme Treatment Manufacturing Base Distribution, Production Area and Product Type
3.5 Glioblastoma Multiforme Treatment Market Competitive Situation and Trends
3.5.1 Glioblastoma Multiforme Treatment Market Concentration Rate
3.5.2 Glioblastoma Multiforme Treatment Market Share of Top 3 and Top 5 Manufacturers
3.5.3 Mergers & Acquisitions, Expansion

Chapter 4 Global Glioblastoma Multiforme Treatment Production, Revenue (Value) by Region (2014-2021)
4.1 Global Glioblastoma Multiforme Treatment Production by Region (2014-2021)
4.2 Global Glioblastoma Multiforme Treatment Production Market Share by Region (2014-2021)
4.3 Global Glioblastoma Multiforme Treatment Revenue (Value) and Market Share by Region (2014-2021)
4.4 Global Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2021)
4.5 North America Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2021)
4.6 Europe Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2021)
4.7 China Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2021)
4.8 Japan Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2021)
4.9 Southeast Asia Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2021)
4.10 India Glioblastoma Multiforme Treatment Production, Revenue, Price and Gross Margin (2014-2021)

Chapter 5 Global Glioblastoma Multiforme Treatment Supply (Production), Consumption, Export, Import by Regions (2014-2021)
5.1 Global Glioblastoma Multiforme Treatment Consumption by Regions (2014-2021)
5.2 North America Glioblastoma Multiforme Treatment Production, Consumption, Export, Import by Regions (2014-2021)
5.3 Europe Glioblastoma Multiforme Treatment Production, Consumption, Export, Import by Regions (2014-2021)
5.4 China Glioblastoma Multiforme Treatment Production, Consumption, Export, Import by Regions (2014-2021)
5.5 Japan Glioblastoma Multiforme Treatment Production, Consumption, Export, Import by Regions (2014-2021)
5.6 Southeast Asia Glioblastoma Multiforme Treatment Production, Consumption, Export, Import by Regions (2014-2021)
5.7 India Glioblastoma Multiforme Treatment Production, Consumption, Export, Import by Regions (2014-2021)

Chapter 6 Global Glioblastoma Multiforme Treatment Production, Revenue (Value), Price Trend by Type
6.1 Global Glioblastoma Multiforme Treatment Production and Market Share by Type (2014-2021)
6.2 Global Glioblastoma Multiforme Treatment Revenue and Market Share by Type (2014-2021)
6.3 Global Glioblastoma Multiforme Treatment Price by Type (2014-2021)
6.4 Global Glioblastoma Multiforme Treatment Production Growth by Type (2014-2021)

Chapter 7 Global Glioblastoma Multiforme Treatment Market Analysis by Application
7.1 Global Glioblastoma Multiforme Treatment Consumption and Market Share by Application (2014-2021)
7.2 Global Glioblastoma Multiforme Treatment Consumption Growth Rate by Application (2014-2021)
7.3 Market Drivers and Opportunities
7.3.1 Potential Applications
7.3.2 Emerging Markets/Countries

Chapter 8 Glioblastoma Multiforme Treatment Manufacturing Cost Analysis
8.1 Glioblastoma Multiforme Treatment Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of Glioblastoma Multiforme Treatment

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers
9.1 Glioblastoma Multiforme Treatment Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Glioblastoma Multiforme Treatment Major Manufacturers in 2020
9.4 Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List

Chapter 11 Market Effect Factors Analysis
11.1 Technology Progress/Risk
11.1.1 Substitutes Threat
11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change

Chapter 12 Global Glioblastoma Multiforme Treatment Market Forecast (2021-2028)
12.1 Global Glioblastoma Multiforme Treatment Production, Revenue Forecast (2021-2028)
12.2 Global Glioblastoma Multiforme Treatment Production, Consumption Forecast by Regions (2021-2028)
12.3 Global Glioblastoma Multiforme Treatment Production Forecast by Type (2021-2028)
12.4 Global Glioblastoma Multiforme Treatment Consumption Forecast by Application (2021-2028)
12.5 Glioblastoma Multiforme Treatment Price Forecast (2021-2028)

Chapter 13 Appendix